Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,919,808 shares of the medical research company’s stock after acquiring an additional 12,168 shares during the quarter. Vanguard Group Inc. owned 6.86% of Bio-Rad Laboratories worth $630,676,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Venturi Wealth Management LLC grew its position in Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after purchasing an additional 87 shares during the last quarter. Picton Mahoney Asset Management lifted its stake in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock worth $32,000 after buying an additional 35 shares during the period. Asset Planning Inc purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at $33,000. UMB Bank n.a. increased its position in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares during the period. Finally, Cape Investment Advisory Inc. purchased a new position in Bio-Rad Laboratories in the 4th quarter worth $38,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Down 1.5 %

Shares of NYSE:BIO opened at $243.33 on Monday. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12-month low of $241.87 and a 12-month high of $387.99. The business has a 50 day moving average of $293.54 and a two-hundred day moving average of $322.50. The company has a market capitalization of $6.82 billion, a PE ratio of -3.74 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.